Aytu BioPharma Files 10-Q, Reports Q2 Revenue

TL;DR

AYTU 10-Q filed: $6.17M revenue, warrants exercised at pennies.

AI Summary

Aytu BioPharma, Inc. filed its 10-Q for the period ending December 31, 2024. The company reported $6,169,681 in revenue for the period. A significant event noted was the exercise of 176,000 Tranche B Pre-Funded Warrants in the first quarter of fiscal 2025, which were liability-classified and exercised at $0.0001 per share.

Why It Matters

This filing provides investors with a financial update on Aytu BioPharma's performance and key events, including warrant exercises, which can impact share structure and financial obligations.

Risk Assessment

Risk Level: medium — The company's financial performance and the details of warrant exercises suggest potential financial complexities and market sensitivity.

Key Numbers

• $6.17M — Revenue (Reported for the period ending December 31, 2024.)
• 176,000 — Warrants Exercised (Tranche B Pre-Funded Warrants exercised in Q1 fiscal 2025.)
• $0.0001 — Warrant Exercise Price (Price at which Tranche B Pre-Funded Warrants were exercised.)

Key Players & Entities

• AYTU BIOPHARMA, INC (company) — Filer of the 10-Q
• 20241231 (date) — End of reporting period
• 20250212 (date) — Filing date
• $6,169,681 (dollar_amount) — Revenue for the period
• 176,000 (dollar_amount) — Number of Tranche B Pre-Funded Warrants exercised
• $0.0001 (dollar_amount) — Exercise price per share for warrants

FAQ

Key Financial Figures

• $0.0001 — ich registered Common Stock, par value $0.0001 per share AYTU The Nasdaq Capital M

Filing Documents

• aytu20241231c_10q.htm (10-Q) — 1532KB
• ex_768099.htm (EX-10.2) — 48KB
• ex_751135.htm (EX-31.1) — 13KB
• ex_751136.htm (EX-31.2) — 13KB
• ex_751137.htm (EX-32.1) — 8KB
• aytu20231231_10qimg001.jpg (GRAPHIC) — 3KB
• 0001437749-25-003568.txt ( ) — 9102KB
• aytu-20241231.xsd (EX-101.SCH) — 80KB
• aytu-20241231_cal.xml (EX-101.CAL) — 67KB
• aytu-20241231_def.xml (EX-101.DEF) — 545KB
• aytu-20241231_lab.xml (EX-101.LAB) — 454KB
• aytu-20241231_pre.xml (EX-101.PRE) — 598KB
• aytu20241231c_10q_htm.xml (XML) — 1658KB

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION 4 Item 1.

Financial Statements

Financial Statements 4 Unaudited Consolidated Balance Sheets 4 Unaudited Consolidated Statements of Operations 5 Unaudited Consolidated Statements of Stockholders' Equity 6 Unaudited Consolidated Statements of Cash Flows 7 Notes to the Unaudited Consolidated Financial Statements 8 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 33 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 40 Item 4.

Controls and Procedures

Controls and Procedures 40

- OTHER INFORMATION

PART II - OTHER INFORMATION 41 Item 1.

Legal Proceedings

Legal Proceedings 41 Item 1A.

Risk Factors

Risk Factors 42 Item 5. Other Information 43 Item 6. Exhibits 44

SIGNATURES

SIGNATURES 45 2 Table of Contents CAUTIONARY INFORMATION REGARDING FORWARD-LOOKING STATEMENTS This Report on Form 10Q ("Form 10-Q" or "this report") includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended ("Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended ("Exchange Act"). All statements other than statements of historical facts contained in this report, including statements regarding our anticipated future clinical and regulatory events, future financial position, business strategy and plans and objectives of management for future operations, are forward-looking statements. Forward looking statements are generally written in the future tense and/or are preceded by words such as "may," "will," "should," "forecast," "could," "expect," "suggest," "believe," "estimate," "continue," "anticipate," "intend," "potential," "plan," or similar words, or the negatives of such terms or other variations on such terms or comparable terminology. Such forward-looking statements include, without limitation: our anticipated future cash position; the planned expanded commercialization of our products and the potential future commercialization of our product candidates; our anticipated future growth rates; anticipated sales increases; anticipated net revenue increases; amounts of certain future expenses and cost of sales; our plans to acquire additional assets or dispose of assets, anticipated increases or decreases to operating expenses, and selling, general, and administrative expenses; and future events under our current and potential future collaborations. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including without limitation the risks described in "Risk Factors" in Part I, Item 1A of our Annual Report on Form 10K for the year ended June 30, 2024 (" 2024 Form 10-K "), and in the reports we file with the United States Securities

FINANCIAL STATEMENTS

ITEM 1. FINANCIAL STATEMENTS AYTU BIOPHARMA, INC. UNAUDITED CONSOLIDATED BALANCE SHEETS (in thousands, except share data) December 31, June 30, 2024 2024 ASSETS Current assets: Cash and cash equivalents $ 20,398 $ 20,006 Accounts receivable, net 25,403 23,526 Inventories 11,085 12,141 Prepaid expenses and other current assets 6,167 5,097 Current assets of discontinued operations — 1,121 Total current assets 63,053 61,891 Non-current assets: Property and equipment, net 516 693 Operating lease right-of-use assets 1,178 829 Intangible assets, net 49,958 52,453 Other non-current assets 1,522 2,185 Non-current assets of discontinued operations — 44 Total non-current assets 53,174 56,204 Total assets $ 116,227 $ 118,095 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 11,699 $ 10,314 Accrued liabilities 39,372 38,143 Revolving credit facility 4,012 2,395 Current portion of debt 1,857 1,857 Other current liabilities 7,108 8,962 Current liabilities of discontinued operations — 557 Total current liabilities 64,048 62,228 Non-current liabilities: Debt, net of current portion 9,983 10,877 Derivative warrant liabilities 6,386 12,745 Other non-current liabilities 5,045 4,529 Total non-current liabilities 21,414 28,151 Commitments and contingencies (note 13) Stockholders' equity: Preferred stock, par value $ .0001 ; 50,000,000 shares authorized; no shares issued or outstanding — — Common stock, par value $ .0001 ; 200,000,000 shares authorized; 6,169,681 and 5,972,638 shares issued and outstanding, respectively 1 1 Additional paid-in capital 348,475 347,688 Accumulated deficit ( 317,711 ) ( 319,973 ) Total stockholders' equity 30,765 27,716 Total liabilities and stockholders' equity $ 116,227 $ 118,095 The accompanying notes to the unaudited consolidated financial statements are an integral part of this statement. 4 Table of Contents

View Full Filing

View this 10-Q filing on SEC EDGAR